EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it closed its previously announced registered direct offering of an aggregate of 10,625,000 units, each unit consisting of (i) one share of common stock and (ii) one warrant to purchase 0.4 shares of common stock at an exercise price of $1.00 per share, for a purchase price of $0.80 per unit. The shares of common stock and warrants are immediately separable and will be issued separately. Cowen and Company, LLC, a subsidiary of Cowen Group, Inc. (Nasdaq: COWN), acted as the lead placement agent for the transaction. Oppenheimer & Co., Inc. and Ladenburg Thalmann & Co. Inc. acted as co-placement agents for the transaction.
